Equities

Viking Therapeutics Inc

Viking Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)76.43
  • Today's Change-3.15 / -3.96%
  • Shares traded4.07m
  • 1 Year change+245.52%
  • Beta1.1180
Data delayed at least 15 minutes, as of May 01 2024 21:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

  • Revenue in USD (TTM)0.00
  • Net income in USD-93.72m
  • Incorporated2012
  • Employees28.00
  • Location
    Viking Therapeutics Inc9920 Pacific Heights Blvd, Suite 350SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 704-4660
  • Fax+1 (302) 636-5454
  • Websitehttps://vikingtherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jazz Pharmaceuticals PLC3.83bn414.83m6.90bn2.80k18.111.856.541.806.126.1253.2060.030.3450.66455.651,369,359.003.761.484.231.6288.6488.7910.904.261.852.060.60480.004.7815.19285.14-1.49-20.04--
Exelixis Inc1.83bn207.77m6.92bn1.31k36.253.1429.623.780.64720.64725.697.480.60872.878.091,397,105.006.918.867.859.9196.0496.3011.3515.433.30--0.000.0013.6016.4713.98-21.343.98--
Bellring Brands Inc1.73bn165.20m7.23bn420.0044.57--34.284.171.241.2412.99-2.192.395.899.624,129,762.0022.7818.8929.01--32.0832.449.5210.101.714.391.530.0021.5315.03101.0913.80-18.48--
Intra-Cellular Therapies Inc464.37m-139.67m7.58bn610.00--11.70--16.33-1.46-1.464.846.140.62621.904.91761,262.30-18.84-38.27-21.89-42.7792.73---30.08-128.425.31--0.00--85.51--45.49---7.22--
Cerevel Therapeutics Holdings Inc0.00-432.84m7.76bn334.00--11.50-----2.66-2.660.003.710.00----0.00-38.29---41.29--------------0.3337-------23.14------
Legend Biotech Corp (ADR)285.14m-518.25m7.96bn1.80k--6.36--27.90-2.95-2.951.626.880.17949.685.70158,412.80-32.60-37.71-38.89-47.1949.42---181.75-286.516.83-24.230.208--143.7042.15-16.11--1.57--
KBR Inc7.07bn-258.00m8.74bn34.00k--6.21--1.24-1.91-1.9152.6710.461.25--5.56207,970.60-4.450.4725-6.460.667813.8612.18-3.580.4122--1.170.5678340.005.977.20-240.21--36.3111.03
Viking Therapeutics Inc0.00-93.72m8.78bn28.00--9.39-----0.9305-0.93050.008.470.00----0.00-16.76-21.91-17.52-23.04------------0.00-------24.73------
Roivant Sciences Ltd123.24m4.35bn8.78bn904.002.151.442.0671.275.075.230.15977.570.0259--3.57136,328.5089.08--105.17--87.57--3,439.02--27.77--0.0638--10.84---32.93------
Repligen Corp638.76m41.58m9.17bn1.78k227.834.6583.6114.350.72070.720711.2735.350.23881.475.31358,252.401.554.381.745.0349.3555.436.5115.915.75--0.22720.00-20.3126.91-77.6420.1324.99--
BIO-TECHNE Corp1.14bn224.12m9.94bn3.05k45.605.0629.718.681.391.397.0912.500.44952.215.84375,409.508.809.579.2810.2067.1367.3519.5821.913.0318.860.185424.192.8112.074.8825.1312.810.00
Catalent Inc4.10bn-1.30bn10.11bn17.80k--2.74--2.47-7.18-7.1822.5220.370.38784.093.00230,224.70-12.322.88-14.023.2617.9431.03-31.776.351.71-0.6250.57580.00-11.2211.59-153.00--26.69--
United Therapeutics Corporation2.33bn984.80m10.39bn1.17k11.821.8410.014.4619.8219.8246.83127.230.35232.419.321,992,723.0014.9110.3816.3311.2788.9491.4742.3129.254.28--0.10470.0020.207.4135.4010.894.55--
Exact Sciences Corp2.50bn-204.15m10.91bn6.50k--3.424,437.384.37-1.14-1.1413.8117.340.39375.3213.82384,579.40-3.22-9.71-3.47-10.6073.8374.10-8.17-28.212.07--0.4311--19.9340.6367.26---3.71--
Data as of May 01 2024. Currency figures normalised to Viking Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

44.59%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 202314.94m13.66%
BlackRock Fund Advisorsas of 31 Dec 20236.39m5.84%
SSgA Funds Management, Inc.as of 31 Dec 20235.73m5.24%
Viking Global Investors LPas of 31 Dec 20235.15m4.71%
The Vanguard Group, Inc.as of 31 Dec 20235.13m4.69%
AllianceBernstein LPas of 31 Dec 20233.67m3.36%
Balyasny Asset Management LPas of 31 Dec 20232.24m2.05%
American Century Investment Management, Inc.as of 31 Dec 20232.22m2.03%
Geode Capital Management LLCas of 31 Dec 20232.13m1.95%
Morgan Stanley & Co. LLCas of 31 Dec 20231.16m1.06%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.